甲胎蛋白、甲胎蛋白异质体与肿瘤坏死因子α检测在原发性肝癌诊断中的应用价值

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨甲胎蛋白（AFP）、甲胎蛋白异质体（AFP-L3）与肿瘤坏死因子α（TNF-α）检测在原发性肝癌诊断中的应用价值。方法选取2019年1月至12月在衡阳市中心医院接受治疗的50 例原发性肝癌患者作为研究组，并选取同时期来衡阳市中心医院体检的50 例健康者为对照组。两组均进行AFP、AFP-L3、TNF-α 检测，比较并分析两组的AFP、AFP-L3 与TNF-α 检测结果，研究不同病理分期患者的检测结果以及联合检测的诊断效能。结果研究组的AFP、AFP-L3 与TNF-α 水平高于对照组，差异有统计学意义（P＜0.05）。肿瘤分期为Ⅲ～Ⅳ期患者的AFP、AFP-L3 与TNF-α 水平高于肿瘤分期为Ⅰ～Ⅱ期患者，差异有统计学意义（P＜0.05）；中分化组、高分化组患者的AFP、AFP-L3 与TNF-α 水平低于低分化组，差异有统计学意义（P＜0.05）；AFP、AFP-L3 与TNF-α 指标联合检测的敏感度高于单独检测，差异有统计学意义（P＜0.05）。结论对原发性肝癌患者进行AFP、AFP-L3 以及TNF-α联合检测，能够对患者病情严重程度进行反映，检测的敏感度较高，利于临床应用及推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张丹霞
	张永虎
	桂若虎
	王晓洋
	伍友兴

关键词 ：原发性肝癌, 甲胎蛋白, 甲胎蛋白异质体, 肿瘤坏死因子&alpha, 诊断效能

Abstract：Objective To explore the application value of α-fetoprotein(AFP),α-fetoprotein heterogenes(AFP-L3)and tumor necrosis factor-α(TNF-α)detection in the diagnosis of primary liver cancer.Methods Fifty patients with primary liver cancer who were treated in Hengyang Central Hospital from January to December 2019 were selected as the research group,and 50 healthy people who came to Hengyang Central Hospital for physical examination during the same period were selected as the control group.The two groups of personnel were tested for AFP,AFP-L3 and TNF-α.The two groups were compared and analyzed for AFP,AFP-L3 and TNF-α test results,test results of patients with different pathological stages in the study group and the diagnostic power of the combined test.Results The levels of AFP,AFP-L3 and TNF-α of the study group were higher than those of the control group,the differences were statistically significant(P＜0.05).The levels of AFP,AFP-L3 and TNF-α in patients with tumor stage of Ⅲ-Ⅳwere higher than those in patients with tumor stage of Ⅰ-Ⅱ,and the differences were statistically significant(P＜0.05).The levels of AFP,AFP-L3 and TNF-α of patients in the moderately differentiated group and the well-differentiated group were lower than those of the poorly differentiated group,and the differences were statistically significant(P＜0.05).The sensitivity of the combined detection of AFP,AFP-L3 and TNF-α indicators were higher than those of independent detection,and the differences were statistically significant(P＜0.05).Conclusion The combined detection of AFP,AFP-L3 and TNF-α in patients with primary liver cancer can reflect the severity of the patient′s condition,and the detection is highly sensitive,which is beneficial to clinical application and promotion.

Key words： Primary liver cancer &alpha -fetoprotein &alpha -fetoproteine heterogeneity Tumor necrosis factor-&alpha Diagnostic power

引用本文:

张丹霞；张永虎；桂若虎；王晓洋；伍友兴. 甲胎蛋白、甲胎蛋白异质体与肿瘤坏死因子α检测在原发性肝癌诊断中的应用价值[J]. 中国当代医药, 2021, 28(26): 223-225转229.
ZHANG Dan-xia；ZHANG Yong-hu； GUI Ruo-hu； WANG Xiao-yang； WU You-xing. Diagnostic value of α-fetoprotein,α-fetoprotein heterogenes and tumor necrosis factor-α in the diagnosis of primary liver cancer. 中国当代医药, 2021, 28(26): 223-225转229.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I26/223

[1]	韩素桂，黄彩云，郑璇，等.比较用凝集素微量离心柱法和酶联免疫吸附法检测甲胎蛋白异质体对原发性肝癌的诊断价值[J].中国临床药理学杂志，2018，34（13）：1517-1519.
[2]	胡仁智，赵世巧，申波，等.血清甲胎蛋白及其异质体和异常凝血酶原对原发性肝癌的诊断价值[J].中华肝脏病杂志，2019，27（8）：634-637.
[3]	郝锐，郑雪松，张莲莲，等.5 种血清标志物在肝癌诊断中的应用价值[J].中国地方病防治杂志，2018，33（2）：9-11.
[4]	程田，唐振林.甲胎蛋白低中浓度肝细胞癌AFP-L3 和Hsp90α 联合检测临床意义[J].中华肿瘤防治杂志，2018，25（21）：1511-1514.
[5]	杨璇，孙桂荣，席强，等.高敏甲胎蛋白异质体比率在肝细胞癌诊治中的临床应用[J].中华消化杂志，2019，39（3）：181-186.
[6]	孙智珺，夏天.CT 联合血清AFP、TSGF、GP73 水平检测对原发性肝癌诊断效能的影响[J].中国地方病防治杂志，2018，33（2）：229，231.
[7]	程田，唐振林.甲胎蛋白低中浓度肝细胞癌AFP-L3 和Hsp90α 联合检测临床意义[J].中华肿瘤防治杂志，2018，25（21）：42-45.
[8]	崔琦，董延娥，霍云龙，等.血清AFP、GP73、SF、DCP 联合检测在原发性肝癌诊断中的应用[J].中国医科大学学报，2019，48（5）：434-436.
[9]	Liu Z，Jiang Y，Yuan H，et al.The trends in incidence of primary liver cancer caused by specific etiologies：Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J].J Hepatol，2019，70（4）：674-683.
[10]	查俊豪，陆建，郭金和.异常凝血酶原联合甲胎蛋白评价原发性肝癌TACE 治疗价值[J].介入放射学杂志，2019，28（6）：591-594.
[11]	李岩，郭鹏，田月洋.黄芩汤联合序贯肝动脉化疗栓塞术对原发性肝癌患者核因子κB 及细胞缺氧诱导因子-1α的影响[J].中华中医药杂志，2019，34（8）：3870-3873.
[12]	王希君，沈容芳，王想，等.甲胎蛋白高表达和低表达肝细胞肝癌的基因表达谱差异分析[J].中华肿瘤杂志，2020，42（5）：396-402.
[13]	Drake TM，Bird TG.Editorial：simplifying screening for primary liver cancer-do the LCR1 and LCR2 tests hold the key?[J].Aliment Pharm Ther，2019，49（5）：612-613.
[14]	查颖，谭娜，曾鹏飞，等.乙肝肝硬化癌变患者血清AFPL3 及HBVDNA 的变化及其可能的临床意义[J].东南大学学报（医学版），2019，38（3）：481-485.
[15]	Tavartkiladze L，Tavartkiladze A，Sordia T，et al.Chronotherapeutic regimen with liposomal cisplatin for systemic treatment of primary liver cancer[J].J Clin Oncol，2019，37（15）：e15678.
[16]	黄彩云，王晓蕊，李世龙，等.CT 扫描联合肿瘤标志物AFP-L3，GP73 诊断原发性肝癌的价值探讨[J].现代肿瘤医学，2019，27（1）：79-82.
[17]	郭致平，殷芳.甲胎蛋白、亮氨酸氨基肽酶及α-L-岩藻糖苷酶表达水平单独和联合检测诊断原发性肝癌的应用价值[J].中国综合临床，2020，36（2）：109-113.